Figure 1.
Simplified scheme of postulated mechanisms by which tezepelumab might reduce asthma exacerbations: (1) reduced IL-5 driven eosinophilic inflammation, (2) decreased mucus production and mucus plugging, and (3) attenuated AHR. This illustration was created using BioRender.com. AHR = airway hyperresponsiveness; CYSLTR1 = cysteinyl leukotriene receptor 1; DC = dendritic cell; FcεRI = Fc epsilon receptor I; FeNO = fractional exhaled nitric oxide; ILC2 = type 2 innate lymphoid cell; iNOS = inducible nitric oxide synthase; MHC-II = major histocompatibility complex II; TCR = T cell receptor; Th2 = T-helper type 2; TSLP = thymic stromal lymphopoietin; TSLPR = thymic stromal lymphopoietin receptor.